3-氯-4-硝基苄醇 | 113372-68-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-4-硝基苄醇
• 英文名称: 3-chloro-4-nitrobenzyl alcohol
• 英文别名: (3-Chloro-4-nitrophenyl)methanol
• CAS: 113372-68-2
• 化学式: C₇H₆ClNO₃
• mdl: MFCD11848698
• 分子量: 187.583
• InChiKey: ZJVGZPXKLAORCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氯-4-硝基苄醇 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 以98%的产率得到3-氯-4-硝基苯甲醛
  参考文献：
  名称：

  Minor structural modifications to Pracinostat produce big changes in its biological responses

  摘要：

  AbstractA series of compounds similar to Pracinostat that contained benzimidazole ring and N‐hydroxyacrylamide attached at 5‐ or 6‐position were designed, synthesized, and evaluated as HDAC inhibitors. It was interesting to find that the corresponding derivative 1 with N‐hydroxyacrylamide attached at 5‐position was a potent HDAC inhibitor while the others at 6‐position were not. This is the first time to demonstrate the position difference plays important role in the HDAC inhibitory activities of the cinnamic hydroxamates.

  DOI：

  10.1111/cbdd.13527
• 作为产物：
  描述：

  3-chloro-4-nitrobenzyl benzoate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 0.17h， 以55%的产率得到3-氯-4-硝基苄醇
  参考文献：
  名称：

  Silk, Nicholas A.; Martin, Carl N., Journal of Chemical Research, Miniprint, 1987, # 8, p. 2133 - 2139

  摘要：

  DOI：

文献信息

• [EN] BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE<br/>[FR] COMPOSÉS BENZIMIDAZOLE ET AZABENZIMIDAZOLE QUI INHIBENT LA KINASE DES LYMPHOMES ANAPLASIQUES
  申请人：AMGEN INC

  公开号：WO2012018668A1

  公开（公告）日：2012-02-09

  Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.

  公式（I）的化合物是有用的间变性淋巴瘤激酶抑制剂。公式（I）的化合物具有以下结构：其中变量的定义如下。
• Molybdenum Hexacarbonyl and DBU Reduction of Nitro Compounds under Microwave Irradiation
  作者：John Spencer、Nazira Anjum、Hiren Patel、Rajendra Rathnam、Jason Verma

  DOI：10.1055/s-2007-986628

  日期：2007.10

  An ethanolic mixture of molybdenum hexacarbonyl and DBU mediates the reduction of nitroarenes to the corresponding anilines in excellent yields in 15-30 minutes under microwave ­irradiation.

  一种乙醇混合的六碳酰钼和DBU在微波辐射下能够在15-30分钟内将硝基芳烃还原为相应的苯胺，产率极高。
• BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE
  申请人：Boezio Christiane M.

  公开号：US20130217668A1

  公开（公告）日：2013-08-22

  Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.

  公式（I）的化合物是阿纳普拉斯腺瘤激酶的有用抑制剂。公式（I）的化合物具有以下结构：其中变量的定义在此提供。
• [EN] BORIC ACID DERIVATIVE<br/>[FR] DÉRIVÉ D'ACIDE BORIQUE<br/>[ZH] 硼酸衍生物
  申请人：SHOUYAO HOLDINGS BEIJING CO LTD

  公开号：WO2021143924A1

  公开（公告）日：2021-07-22

  式(I)所示的硼酸衍生物或其药学上可接受的盐、溶剂化物、多晶型物或异构体，包含这些化合物的药物组合物，以及此类化合物在治疗跟lmp7相关的疾病中的用途。
• Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity
  作者：Edward J. Hennessy、Vibha Oza、Ammar Adam、Kate Byth、Lillian Castriotta、Gurmit Grewal、Geraldine A. Hamilton、Victor M. Kamhi、Paula Lewis、Danyang Li、Paul Lyne、Linda Öster、Michael T. Rooney、Jamal C. Saeh、Li Sha、Qibin Su、Shengua Wen、Yafeng Xue、Bin Yang

  DOI：10.1021/acs.jmedchem.5b01078

  日期：2015.9.10

  We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P(1) receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compounds described previously. Lead compound 2 potently inhibits SIP-induced receptor internalization in a cell-based assay (EC50 = 0.05 mu M), but has poor physical properties and metabolic stability. Evolution of this compound through structure-activity relationship development and property optimization led to in vivo probes such as 4. However, this compound was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chemistry efforts were directed at addressing this liability. By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compounds for further testing in human hepatocytes, we identified lipophilicity as a key molecular property influencing the likelihood of P450 induction. Ultimately, we have identified compounds such as 46 and 47, which demonstrate the desired S1P(1) antagonist activity while having greatly reduced risk of CYP3A induction in humans. These compounds have excellent oral bioavailability in preclinical species and exhibit pharmacodynamic effects of S1P(1) antagonism in several in vivo models following oral dosing. Relatively modest antitumor activity was observed in multiple xenograft models, however, suggesting that selective S1P(1) antagonists would have limited utility as anticancer therapeutics as single agents.